Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.51) per share. This is a 92.28 percent increase over losses of $(6.61) per share from the same period last year.
Evolv Technologies Granted U.S. Patent #11568734: Personnel Inspection With Threat Detection And Discrimination
https://www.scribd.com/document/622998416/EVLV-Patent